News

Merck & Co., Inc. (MRK)’s CEO Thinks He’s Got $50 Billion Of New Drugs, Says Jim Cramer
We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently discussed. Merck & Co., Inc.
Merck's Verona Acquisition: Plugging A $4B Hole In A $20B Gap
Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...
Merck & Co.: A Pharma Titan At A Discount
Merck is a massive company with strong fundamentals and underlying value at a heavily discounted price. Click here to find ...
Merck buys Raleigh pharma company for $10 billion, drawn by new COPD drug
Verona Pharma's flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease ...
GEN - Genetic Engineering and Biotechnology News2d
Merck to Acquire Verona Pharma for $10B, Adding Fast-Growing COPD Drug
Merck & Co. has agreed to acquire Verona Pharma for $10 billion, the companies said, in a deal designed to expand the pharma ...
Merck: FDA to Review Doravirine/Islatravir Regimen in HIV-1 Infection
Merck on Thursday said the application covers the investigational, once-daily, oral two-drug regimen for adults with HIV-1 infection that is virologically suppressed on antiretroviral therapy. The ...
Freshfields, Latham Guide Merck’s $10 Billion Plan to Buy Verona
Two Big Law firms guided Merck & Co.'s plans to purchase respiratory drugmaker Verona Pharma Plc for around $10 billion.
UBS Affirms Merck & Co’s (MRK) ‘Buy’ Rating on HPV Vaccine Prospects
Merck & Co., Inc. (NYSE:MRK) is one of the 10 best defensive stocks to buy in a volatile market. On July 2, UBS reiterated a ...